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Dietary nutrients interact with gene networks to
orchestrate adaptive responses during metabolic
stress. Here, we identify Baf60a as a diet-sensitive
subunit of the SWI/SNF chromatin-remodeling com-
plexes in the mouse liver that links the consumption
of fat- and cholesterol-rich diet to elevated plasma
cholesterol levels. Baf60a expression was elevated
in the liver following feeding with a western diet.
Hepatocyte-specific inactivation of Baf60a reduced
bile acid production and cholesterol absorption,
and attenuated diet-induced hypercholesterolemia
and atherosclerosis in mice. Baf60a stimulates
expression of genes involved in bile acid synthesis,
modification, and transport through a CAR/Baf60a
feedforward regulatory loop. Baf60a is required for
the recruitment of the SWI/SNF chromatin-remodel-
ing complexes to facilitate an activating epigenetic
switch on target genes. These studies elucidate
a regulatory pathway that mediates the hyper-
lipidemic and atherogenic effects of western diet
consumption.
INTRODUCTION
Elevated plasma low-density lipoprotein (LDL) cholesterol is a
major risk factor for atherosclerosis and its associated cardio-
vascular mortality and morbidity (Glass and Witztum, 2001;
Ross, 1993; Steinberg, 2002). The cholesterol pool in the body
is tightly regulated by feedback mechanisms that impinge on
endogenous cholesterol biosynthesis, catabolism, and excretion
as bile acid (Chiang, 2009; Goldstein and Brown, 2015). Accu-
mulation of intracellular sterol prevents the proteolytic activation
of the sterol-response element binding protein (Srebp), tran-
scriptional regulators of cholesterol biosynthesis, while stimu-
lating the expression of genes involved in bile acid formation
and excretion (Brown and Goldstein, 2009; Chiang, 2009). Phar-1658 Cell Reports 13, 1658–1669, November 24, 2015 ª2015 The Aumacological targeting of these pathways has proved effective in
lowering LDL cholesterol and reducing the risk of atherosclerosis
(Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults, 2001; Grundy et al., 2004; Waters
et al., 2009).
Nuclear hormone receptors have been implicated in sen-
sing diverse metabolites in the cell, including lipids, oxy-
sterols, bile acids, and xenobiotic compounds (Evans and
Mangelsdorf, 2014). Hepatocytes sense the enterohepatic
flux of cholesterol and bile acids in part through engaging liver
X receptor (LXR) and farnesoid X receptor (FXR) (Calkin and
Tontonoz, 2012; Matsubara et al., 2013). Oxysterols are
oxygenated derivatives of cholesterol that serve as LXR li-
gands. A major target gene of LXR is Cyp7a1, which catalyzes
the first step of the classic bile acid synthesis pathway (Leh-
mann et al., 1997; Peet et al., 1998). An alternative pathway
initiated by sterol-27 hydroxylase (Cyp27a1) also contributes
to cholesterol catabolism to bile acids (Schwarz et al.,
2001). Bile acids are efficiently recycled through the enterohe-
patic circulation to facilitate intestinal absorption of dietary
fats (Thomas et al., 2008). Accumulation of bile acids in hepa-
tocytes results in FXR activation and induction of its target
gene small heterodimer partner (Shp), which mediates the
feedback inhibition of bile acid synthesis (Goodwin et al.,
2000; Lu et al., 2000). In addition, constitutive androstane re-
ceptor (CAR) and pregnane X receptor (PXR), best known as
xenobiotic sensors, regulate bile acid detoxification by stimu-
lating the expression of hepatic genes responsible for the
modification, conjugation, and transport of bile acids (Li and
Chiang, 2013; Pascussi et al., 2008). Dietary intake of choles-
terol is known to stimulate bile acid synthesis and increase
bile acid pool and fecal excretion in rodents and humans;
however, the nature of dietary regulation of bile acid homeo-
stasis and intestinal lipid absorption remains elusive (Duane,
1994; Tiemann et al., 2004; Xu et al., 1999).
Nuclear receptors activate or repress gene transcription
through recruiting various chromatin-remodeling complexes
to alter the epigenetic landscape of target genomic loci (Chen
and Roeder, 2011; Dasgupta et al., 2014; Mottis et al., 2013).
Despite this, the significance of the nucleosome-remodelingthors
Figure 1. BaLKO Mice Are Resistant to Diet-Induced Hypercholesterolemia
(A) qPCR analysis of liver gene expression in mice fed standard chow or Western diet (WD) for 8 weeks (n = 5).
(B) Left, immunoblots of liver nuclear extracts; right, quantitation of Baf60a protein levels after normalization to Lamin A/C.
(C) qPCR analysis of gene expression in livers from flox/flox and BaLKO mice (n = 5).
(D) Left, immunoblots of liver nuclear extracts; right, quantitation of Baf60a protein levels after normalization to Lamin A/C.
(E–G) Plasma lipid levels (E), lipoprotein profile analysis (F), and concentrations of HDL, LDL/VLDL, and total cholesterol (G) in flox/flox and BaLKOmice following
12 weeks of WD feeding (n = 5). Values are mean ± SEM; *p < 0.05 by two-tailed Student’s t test.
See also Figure S1.complexes, such as the SWI/SNF complexes, in nuclear recep-
tor signaling and metabolic physiology remains poorly under-
stood. The SWI/SNF complexes are composed of one of two
catalytic ATPase subunits (Brg1 or Brm) and additional sub-
units known as Brg/Brm-associated factors (Bafs) (Phelan
et al., 1999; Sudarsanam and Winston, 2000; Wang et al.,
1996; Wu et al., 2009). While Baf47, Baf170, and Baf155 form
part of a core complex with Brg1/Brm, incorporation of other
Baf subunits confers diversity and specificity of SWI/SNF
complexes in transcriptional control. Recent studies have
demonstrated that the Baf60 family members Baf60a and
Baf60c recruit SWI/SNF complexes to regulate metabolic
gene programs in the liver and skeletal muscle (Li et al.,
2008; Meng et al., 2013, 2014). In this study, we identify
Baf60a as a diet-sensitive factor in the liver that controls a
hepatic gene program responsible for bile acid synthesis and
intestinal cholesterol absorption through a Baf60a/CAR feed-
forward regulatory loop. Disruption of this pathway by liver-
specific inactivation of Baf60a protects mice from diet-induced
hypercholesterolemia and atherosclerosis.Cell RepRESULTS
Hepatic Baf60a Is a Diet-Sensitive Regulator of
Cholesterol Homeostasis
Chromatin-remodeling factors link nutrient signaling to meta-
bolic gene programs through altering the epigenetic state of
chromatin. The SWI/SNF complexes play an important role in
differentiation, development, and tumorigenesis (Puri and Mer-
cola, 2012; Wilson and Roberts, 2011); however, their role in
diet-induced hyperlipidemia has not been explored. We
analyzed the expression of core SWI/SNF subunits in the liver
from mice fed standard chow or Western diet (WD); the latter
has been commonly used to induce hypercholesterolemia.
Immunoblotting analysis of liver nuclear extracts indicated
that protein levels of core SWI/SNF subunits, including Brg1,
Baf170, Baf155, and Baf53a, were similar between two groups
(Figures 1A and 1B). In contrast, mRNA and protein levels of
Baf60a were significantly elevated following WD feeding. The
expression levels of Baf60b and Baf60c, two Baf60 familymem-
bers closely related to Baf60a, remained largely insensitive toorts 13, 1658–1669, November 24, 2015 ª2015 The Authors 1659
diets. In addition, hepatic expression of Baf60a was similar be-
tween control and genetic obese mice (Figure S1A). Previous
studies have demonstrated that Baf60a and Baf60c mediate
the recruitments of the SWI/SNF complexes to specific target
genes through their interaction with transcription factors and
cofactors (Debril et al., 2004; Li et al., 2008; Meng et al.,
2013). As such, Baf60a may serve as a diet-sensitive compo-
nent of the SWI/SNF complexes in the liver that links dietary
fat intake to lipid metabolism.
To dissect the role of Baf60a in mediating diet-gene interac-
tion, we generated mice with conditional Baf60a deficiency in
the liver. Mice containing floxed Baf60a alleles were crossed
with Albumin-CRE (Alb-CRE) transgenic mice to generate con-
trol (flox/flox) and liver-specific Baf60a knockout mice (BaLKO,
flox/flox:Alb-CRE) (Figure S1B). As expected, Baf60a mRNA
and protein expression was markedly reduced in BaLKO
mouse livers (Figures 1C and 1D). The expression levels of
Baf60b, Baf60c, and other SWI/SNF subunits remained largely
unaffected by Baf60a deficiency. Further, Baf60a expression
in other metabolic tissues, including skeletal muscle, adipose
tissues, and small intestine, was unaffected in BaLKO mice
(Figures S1C and S1D). BaLKO mice were born at expected
Mendelian ratio and appeared indistinguishable from control
littermates. Plasma lipid concentrations were similar between
two groups when fed standard chow, and, as expected,
control mice exhibited elevated plasma cholesterol levels
following 12 weeks of WD feeding (Figure 1E). In contrast,
BaLKO mice were partially resistant to diet-induced hypercho-
lesterolemia despite similar weight gain (Figures 1E and S1E);
total plasma cholesterol concentration was approximately
40% lower in BaLKO mice than control. Plasma triglycerides
(TAG), non-esterified fatty acids (NEFAs), and fasting blood
glucose levels were similar between two groups following
WD feeding (Figures 1E and S1F). Lipoprotein profile analysis
and quantitative measurements of cholesterol in different lipo-
protein fractions revealed that both LDL/very-low-density lipo-
protein (VLDL) and high-density lipoprotein (HDL) cholesterol
were lower in mice lacking Baf60a in the liver (Figures 1F
and 1G). Together, these findings support a uniquely important
role of Baf60a in mediating diet-induced elevation of plasma
cholesterol levels.
Baf60a Deficiency in Hepatocytes Impairs Bile Acid
Synthesis and Cholesterol Absorption
We next performed transcriptional profiling on the livers from
WD-fed control and BaLKO mice to globally define hepatic
target genes of Baf60a (GEO accession number GSE73709).
Pathway analysis using the Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) revealed that a cluster of
genes involved in primary bile acid biosynthesis was the most
significantly downregulated gene set in response to Baf60a
inactivation in hepatocytes (Figures 2A and 2B). Several nuclear
hormone receptors, including FXR, LXR, CAR, and PXR, have
been reported as important regulators of cholesterol and bile
acid metabolism in the liver (Beaven and Tontonoz, 2006;
Chiang, 2009; Evans and Mangelsdorf, 2014; Gao and Xie,
2012). While mRNA levels for PXR, LXR, and FXR remained
largely unaltered by Baf60a deficiency, the expression of CAR1660 Cell Reports 13, 1658–1669, November 24, 2015 ª2015 The Auwas markedly lower in BaLKO livers than control (Figure 2C).
This decrease in CAR expression correlated with lower expres-
sion of genes involved in bile acid synthesis, including Cyp8b1,
Cyp27a1, Cyp7b1, BAAT, and Hsd3b5, and those involved in
xenobiotic responses and bile acid modification and transport,
such as Cyp2b10, Cyp3a11, Sult5a1, Ugt1a1, Oatp2, Mrp3,
and Mdr2 (Figure 2D). In contrast, the expression of Shp, a ca-
nonical target gene of FXR, and Cyp7a1, Abca1, Abcg5, and
Abcg8, target genes of LXR, remained similar between two
groups (Figure 2E). The expression of hepatic genes involved
in cholesterol biosynthesis (Srebp1a, Srebp1c, Srebp2, Hmgcr,
and Hmgcs1) appeared largely unaffected by Baf60a defi-
ciency. Further, mRNA and protein levels of LDLR, which is
responsible for the uptake of plasma LDL (Brown and Gold-
stein, 1986), and Pcsk9, an important modulator of LDLR
protein levels (Horton et al., 2009), were comparable between
control and BaLKO mice (Figures 2E–2G). Consistently, lipo-
protein secretion analysis indicated that the rise of plasma
cholesterol concentrations following tail-vein injection of tylox-
apol (500 mg/kg) was unaffected by Baf60a deficiency (Fig-
ure S2A). As such, hepatic inactivation of Baf60a appears to
exert modest effects on cholesterol synthesis, LDL uptake,
and lipoprotein secretion. To rule out the possibility that
Baf60a deficiency may impair liver function and cause liver
injury, we measured plasma alanine transaminase (ALT) and
aspartate aminotransferase (AST) levels, and the expression
of marker genes involved in liver fibrosis and inflammation.
Plasma concentrations of ALT and AST were significantly lower
in BaLKO mice than control, whereas the mRNA expression of
genes involved in liver fibrosis and inflammation remained
similar between two groups (Figures S2B and S2C).
As bile acids play an important role in the digestion and
absorption of dietary fats, impaired intestinal cholesterol absorp-
tion may contribute to resistance to diet-induced hypercholes-
terolemia in BaLKO mice. In support of this, total bile volume
and biliary bile acid content were approximately 37% lower in
BaLKO mice than control, whereas plasma and liver bile acid
concentrations remained similar between two groups (Figures
3A and 3B). Measurements of bile acid pool indicated that
liver/gallbladder and intestine bile acid pool sizes were both
significantly lower in BaLKO mice, resulting in lower whole-
body bile acid content (Figure 3C). However, the composition
of different bile acid species in bile from gallbladder remained
similar between two groups (Figure 3D). In parallel, liver choles-
terol content is elevated in BaLKO mice compared to control
(Figure 3E). Consistent with dietary cholesterol being an impor-
tant source of the lipid, cholesterol-lowering effect of hepatic
Baf60a deficiency was abolished following overnight starvation
(Figure 3F). While food intake remained similar between two
groups, cholesterol excretion in feces was significantly higher
in BaLKO mice (Figure 3G), suggesting that hepatic Baf60a
inactivation impaired intestinal cholesterol absorption. Direct
measurements of cholesterol absorption by oral gavage of 3H-
labeled cholesterol indicated that the amounts of radiolabeled
cholesterol in plasma and the liver were significantly lower in
BaLKO mice than control (Figure 3H). Consequently, choles-
terol-lowering effects of ezetimibe, an inhibitor of cholesterol ab-
sorption, failed to further reduce plasma cholesterol levels inthors
Figure 2. Baf60a Regulates CAR and Its Target Genes Involved in Bile Acid Metabolism
(A) DAVID pathway analysis of downregulated genes in BaLKO mouse livers identified by microarray.
(B) Heatmap representation of genes involved in bile acid metabolism.
(C–E) qPCR analysis of the mRNA expression of transcriptional factors (C), CAR target genes (D), and FXR, LXR and PXR target genes (E) involved in bile acid
metabolism in livers from flox/flox and BaLKO mice fed with WD for 12 weeks (n = 5).
(F) Plasma concentrations of Pcsk9 (n = 4–5).
(G) Immunoblots of total liver lysates.
Data in (C)–(F) are mean ± SEM; *p < 0.05 by two-tailed Student’s t test. See also Figure S2.BaLKO mice (Figure 3I). These results illustrate that impaired
cholesterol absorption secondary to reduced bile acid synthesis
likely mediates resistance to diet-induced hypercholesterolemia
in BaLKO mice.
Baf60a Cell-Autonomously Regulates the Bile Acid
Metabolism Gene Program
The marked reduction of CAR expression in the BaLKO mouse
livers suggests that its deficiency may be responsible for lower
expression of genes involved in bile acid metabolism. We next
examined whether Baf60a regulates CAR gene expression in
a cell-autonomous manner. Gene expression analysis of pri-
mary hepatocytes isolated from flox/flox and BaLKO mice
demonstrated that mRNA expression of CAR was approxi-
mately 74% lower in Baf60a-deficient hepatocytes (Figures
4A and 4B). In parallel, mRNA expression of several genes
involved in the alternative pathway of bile acid synthesis,
including Cyp8b1, Cyp27a1, and Cyp7b1, and bile acid modifi-
cation and transport, including BAAT, Hsd3b5, Cyp2b10,
Cyp3a11, Sult5a1, Ugt1a1, Oatp2, Mrp3, and Mdr2, was alsoCell Repsignificantly lower in Baf60a-deficient hepatocytes. Treatments
of hepatocytes with TCPOBOP, a synthetic CAR agonist, signif-
icantly inducedmRNA expression ofCyp2b10, a canonical CAR
target gene, andCAR itself. However, the induction of these two
genes by TCPOBOP was nearly abolished in hepatocytes lack-
ing Baf60a (Figure 4C), indicating that Baf60a is required for
maintaining the expression and transcriptional activity of CAR
in hepatocytes.
To determine whether Baf60a serves as an upstream regu-
lator of CAR, we transduced primary hepatocytes with control
GFP or Baf60a adenoviruses. Gene expression analysis indi-
cated that adenoviral-mediated overexpression of Baf60a re-
sulted in over 10-fold induction of endogenous CAR (Figures
4A and 4D). Importantly, Baf60a stimulated the expression of
Cyp8b1, Cyp27a1, Cyp7b1, and a panel of genes involved in
bile acid modification and transport. Baf60a-mediated induc-
tion of CAR and Cyp2b10was further augmented by TCPOBOP
treatments, suggesting that Baf60a acts in concert with CAR to
regulate the expression of CAR target genes (Figure 4E). To
assess the effects of hepatic Baf60a activation on cholesterolorts 13, 1658–1669, November 24, 2015 ª2015 The Authors 1661
Figure 3. Hepatic Baf60a Regulates Bile Acid Metabolism and Cholesterol Absorption
flox/flox and BaLKO mice were fed with standard chow or WD for 12 weeks.
(A and B) Plasma and hepatic bile acid levels (A) and gallbladder volume, biliary bile acid concentrations, and biliary bile acid content (B) (n = 6–8).
(C) Bile acid pool size in liver plus gallbladder (L+G), intestine, and whole body (Total) (n = 5).
(D) Bile acid composition in the bile from gallbladder. Left, percentile composition of different bile acids in the bile from flox/flox and BaLKO mice; right, con-
centrations of four major bile acids in the bile. T-b-MCA, tauro-b-muricholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; CA, cholic acid;
b-MCA, b-muricholic acid; a-MCA, a-muricholic acid; TLCA, taurolithocholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid.
(E) Concentrations of total cholesterol (TC), free cholesterol (FC), and cholesterol ester (CE) in livers from control (dark bars) and BaLKO (gray bars) mice (n = 6–9).
(F) Plasma cholesterol levels in mice under fed and fasted conditions (n = 6).
(G) Food intake and fecal cholesterol content in WD-fed control and BaLKO mice (n = 4–5).
(H) Cholesterol uptake into plasma and liver following oral gavage of 3H-cholesterol (3H-chol.) for 2 hr.
(I) Plasma cholesterol concentrations inWD-fed control and BaLKOmice treated with vehicle alone (CTR) or ezetimibe (EZ) for 4 days (n = 6); *p < 0.05 versus flox/
flox mice treated with vehicle alone; ns, not significant.
In all panels, values are mean ± SEM; *p < 0.05 by two-tailed Student’s t test.absorption in mice, we transduced WD-fed wild-type mice
with recombinant adenoviruses expressing GFP or Baf60a via
tail-vein injection. Compared to control, mice transduced with
Baf60a adenovirus had significantly elevated total plasma
cholesterol levels (Figure 4F). Gene expression analysis indi-
cated that tail-vein transduction of Baf60a adenovirus signifi-
cantly increased mRNA levels of CAR and its target genes in
the liver (Figure 4G). The expression of LXR, FXR, PXR,
Srebp1a, Srebp1c, Srebp2, and their target genes remained
similar between two groups.1662 Cell Reports 13, 1658–1669, November 24, 2015 ª2015 The AuBaf60a and CAR Form a Feedforward Regulatory Loop
through a SWI/SNF-Mediated Epigenetic Mechanism
The SWI/SNF chromatin-remodeling complexes are recruited
to specific chromatin loci through physical interaction with tran-
scription factors. The BAF60 subunit has been demonstrated to
serve as a molecular link between the core complexes and
DNA-binding factors (Li et al., 2008; Meng et al., 2013, 2014).
To test whether Baf60a physically interacts with CAR, we per-
formed protein-protein interaction assay using coimmunopreci-
pitation (coIP). Baf60a and CAR formed a physical complexthors
Figure 4. Baf60a Regulates the Bile Acid Metabolism Gene Program in a Cell-Autonomous Manner
(A) Heatmap representation of gene regulation in response to Baf60a deficiency (BaLKO/flox/flox) and Baf60a overexpression (Baf60a/GFP) in primary
hepatocytes.
(B and C) qPCR analysis of gene expression in primary hepatocytes isolated from flox/flox and BaLKO mice in the presence or absence of TCPOBOP treatment
(TCP, 1 mM) for 24 hr. In (C), *p < 0.05 versus vehicle treatment alone (the first bar); #p < 0.05 versus TCP treatment alone (the second bar).
(D and E) qPCR analysis of gene expression in primary hepatocytes transduced with GFP or Baf60a adenoviruses and treated with or without TCP 1 mM for 24 hr.
*p < 0.05 versus GFP expression alone; #p < 0.05 versus TCP treatment or Baf60a expression alone.
(F) Plasma cholesterol levels in WD-fed WT mice transduced with adenoviruses expressing GFP or Baf60a.
(G) qPCR analysis of hepatic gene expression in WT mice transduced with adenoviruses expressing GFP or Baf60a.
Data in (B)–(E) representmean ±SD and are representative of three independent experiments; data in (F) and (G) represent mean ±SEM (n = 6); #p < 0.05, and *p <
0.05 by two-tailed Student’s t test.when they were co-expressed in HEK293 cells following tran-
sient transfection (Figure 5A). The physical association between
CAR and Baf60a was further confirmed in HepG2 hepatoma
cells. We transduced HepG2 cells with adenoviruses express-
ing GFP or Flag/HA-tagged CAR (FH-CAR) and performed
immunoprecipitation using anti-HA agarose beads. Immuno-
blotting analyses indicated that, in addition to endogenous
Baf60a, other subunits of the SWI/SNF complexes, including
Brg1, Baf170, Baf155, and Baf53a, were readily detectable in
the CAR immunocomplexes (Figure 5B). These findings sug-
gest that Baf60a mediates the recruitment of the SWI/SNF
chromatin-remodeling complexes to the genomic targets occu-
pied by CAR.
Genomatix motif analysis predicted two putative CAR
Response Elements (CARRE) located approximately 2.0 (RE2)Cell Repand 0.9 kb (RE1) upstream of the transcriptional start site of
CAR gene. Chromatin immunoprecipitation (ChIP) assays
demonstrated that epitope-tagged Baf60a and CAR were re-
cruited to these two sites on the native CAR promoter (Figures
5C and 5D). As such, Baf60a and CAR appear to form a feedfor-
ward regulatory loop to drive the expression of CAR and its
target genes. A prediction of this model is that Baf60a levels
may dictate the recruitment of the SWI/SNF complexes, which,
in turn, has an impact on the local epigenetic landscape. To
test this, we performed ChIP assay in control and Baf60a-
deficient primary hepatocytes. Baf60a deficiency significantly
reduced the recruitment of SWI/SNF core subunit Brg1 to the
chromatin near the CAR binding sites, leading to reduced
levels of acetyl-histone H3 (Ace-H3) and trimethylation of H3
lysine 4 (H3K4m3), two epigenetic markers associated withorts 13, 1658–1669, November 24, 2015 ª2015 The Authors 1663
Figure 5. Baf60a and CAR Form a Feedforward Regulatory Loop
(A) Physical interaction between CAR and Baf60a in transiently transfected 293T cells. IP, immunoprecipitation; Myc-Baf60a, Myc-tagged Baf60a; HA-CAR, HA-
tagged CAR.
(B) Immunoblots of immunoprecipitated proteins or total protein lysates from HepG2 cells transduced with adenoviruses expressing Flag/HA-tagged CAR (FH-
CAR). Note that FH-CAR interacts with endogenous SWI/SNF subunits.
(C and D) Relative enrichment of Baf60a (C) and CAR (D) at the putative CAR binding site on the proximal CAR promoter. RE1, CAR response element 1; RE2, CAR
response element 2.
(E) ChIP assay with chromatin lysates prepared from flox/flox and BaLKO mouse livers using indicated antibodies.
(F) ChIP assay with chromatin lysates prepared from primary hepatocytes transduced with GFP or Baf60a adenoviruses.
(G and H) WD-fed flox/flox and BaLKO mice were transduced with adenoviruses expressing GFP or CAR for 1 week. Shown are qPCR analysis of hepatic gene
expression (G) and measurement of plasma cholesterol levels (H); *p < 0.05, BaLKO GFP versus flox/flox GFP; #p < 0.05, BaLKO CAR versus BaLKO GFP.
Data in (C)–(F) represent mean ± SD and are representative of three independent experiments; data in (G) and (H) represent mean ± SEM (n = 4–5); #p < 0.05, and
*p < 0.05 by two-tailed Student’s t test. See also Figure S3.transcriptional activation (Figure 5E). Conversely, adenoviral-
mediated expression Baf60a augmented the recruitment of
Brg1 and increased Ace-H3 and H3K4m3 levels on the prox-
imal CAR promoter (Figure 5F). There results demonstrate that
Baf60a modulates the transcriptional activity of CAR through
its recruitment of SWI/SNF-mediated chromatin remodeling.
The marked reduction of CAR expression in BaLKO mouse
livers suggest that Baf60a deficiency may disrupt the feedfor-
ward regulatory loop and impair the transcription of CAR target
genes. We next performed rescue studies to determine the sig-1664 Cell Reports 13, 1658–1669, November 24, 2015 ª2015 The Aunificance of CAR inmediating the effects of Baf60a deficiency on
plasma cholesterol. Consistent with previous transgenic studies
(Dong et al., 2009; Saini et al., 2004), tail-vein injection of CAR
adenovirus significantly increased the expression of its target
genes involved in bile acidmetabolism in wild-typemice (Figures
S3A–3C). Adenoviral-mediated rescue of CAR expression in
BaLKO mice to slightly above its endogenous levels restored
the expression of several CAR target genes, including Cyp8b1,
Cyp27a1, BAAT, Cyp2b10, Cyp3a11, Ugt1a1, Oatp2, Mrp3,
and Mdr2 (Figure 5G), and more importantly, reversed plasmathors
Figure 6. Hepatic Inactivation of Baf60a Protects Mice from Diet-Induced Atherosclerosis
(A) Fed and fasting plasma cholesterol levels in flox/flox:ApoE/ and BaLKO:ApoE/ mice fed with WD for 12 weeks (n = 6).
(B) Representative images of en face oil-red-O-stained aortic arches.
(C) Quantification of lesion area (n = 10–15).
(D) qPCR analysis of hepatic gene expression in flox/flox:ApoE/ and BaLKO:ApoE/ mouse livers (n = 6–9).
(E) Schematic model of the Baf60a/CAR feedforward regulatory loop in mediating diet-induced hypercholesterolemia and atherosclerosis.
Data shown in (A), (C), and (D) represent mean ± SEM; *p < 0.05 by two-tailed Student’s t test.cholesterol levels in BaLKO mice (Figure 5H). Although the ex-
pression PXR was not significantly altered in livers from BaLKO
mice, our coIP experiments indicated that Baf60a could also
physically interact with PXR (Figure S3D). As such, PXR may
mediate the transcriptional effects of Baf60a on a subset of
target genes involved in bile acid metabolism and xenobiotic
detoxification. In support of this possibility, adenoviral expres-
sion of CAR failed to restore the expression of Cyp7b1,
Hsd3b5, and Sult5a1 in BaLKO mouse livers. We conclude
from these studies that Baf60a activates a CAR-dependent pro-
gram of gene expression in the liver to facilitate bile acid produc-
tion and intestinal lipid absorption.
Liver-Specific Inactivation of Baf60a ProtectsMice from
Diet-Induced Atherosclerosis
Elevated LDL cholesterol is a major risk factor for atherosclerosis.
ApoE plays an important role in the regulation of plasma choles-
terol through its interaction with LDLR to facilitate the uptake of
cholesterol-rich lipoproteins (Mahley, 1988). ApoE-null (ApoE/)
mice have markedly elevated plasma cholesterol levels and are a
commonly used model of atherosclerosis (Ishibashi et al., 1994;Cell RepPiedrahita et al., 1992). To determine the significance of Baf60a
in cholesterol homeostasis and atherosclerosis,wegenerated co-
horts of flox/flox:ApoE/ and BaLKO:ApoE/ mice and sub-
jected them toWD feeding. Plasma lipid measurements indicated
that hepatocyte-specific inactivation of Baf60a lowered total
plasma cholesterol levels by approximately 30% in ApoE/
background (Figure 6A). The cholesterol-lowering effect was
only observed in BaLKO:ApoE/ mice under fed conditions. To
elucidate the significance of hepatic Baf60a in atherosclerosis,
we performed oil red O staining on the dissected arterial trees
from flox/flox:ApoE/ and BaLKO:ApoE/ mice following
12 weeks of WD feeding. Remarkably, hepatocyte-specific inac-
tivation of Baf60a significantly ameliorated atherosclerotic lesion
formation (Figure 6B). Compared to control, lesion area was
approximately 53% smaller in BaLKO mice (Figure 6C). Gene
expression analysis indicated that the expression of CAR and
its target genes involved in bile acid metabolism was significantly
lower in BaLKO:ApoE/ mouse livers (Figure 6D). Together,
these results illustrate a diet-sensitive epigenetic pathway in the
liver that plays a critical role in lipid absorption, cholesterol ho-
meostasis, and atherosclerosis.orts 13, 1658–1669, November 24, 2015 ª2015 The Authors 1665
DISCUSSION
The interaction between dietary nutrients and the gene net-
works is pivotal for metabolic homeostasis and contributes to
the pathogenesis of complex diseases. Chronic consumption
of fat- and cholesterol-rich diet is known to elevate plasma
cholesterol levels and increase the risk for cardiovascular
diseases (Glass and Witztum, 2001; Ross, 1993; Steinberg,
2002). In this study, we identified Baf60a as a diet-sensitive
subunit of the SWI/SNF chromatin-remodeling complexes in
the liver that serves a critical role in elevating plasma choles-
terol levels following WD feeding. Hepatocyte-specific inacti-
vation of Baf60a partially protects mice from WD-induced
elevation of plasma cholesterol levels and atherosclerosis. At
themechanistic level, hepatic Baf60a is required formaintaining
bile acid homeostasis and intestinal cholesterol absorption
through a CAR/Baf60a feedforward regulatory loop in the liver
(Figure 6E).
Several lines of evidence support a crucial role of Baf60a in bile
acid production and intestinal cholesterol absorption. Transcrip-
tional profiling and pathway analysis indicated that the genes
involved in primary bile acid biosynthesis ranked at the top
among those downregulated by Baf60a deficiency. Interestingly,
the expression of Cyp7a1, a target gene of LXR in the classic
bile acid synthesis pathway, remained largely unchanged. In
contrast, mRNA levels for the genes responsible for the alterna-
tive pathway of bile acid biosynthesis were significantly reduced
in BaLKO mouse livers. Hepatic expression of CAR and a panel
of genes involved in bile acid modification and transport were
also lower in BaLKO mice. Consistently, adenoviral-mediated
Baf60a overexpression was sufficient to induce this set of genes
in cultured primary hepatocytes and in vivo in the liver. The
significance of the alternative pathway was illustrated by signif-
icantly reduced bile acid synthesis and pool size in Cyp27a1-
null mice (Repa et al., 2000; Rosen et al., 1998). Interestingly,
inactivation of Cyp7a1 abolished the primary bile acid biosyn-
thesis pathway and led to induction of the alternative pathway
(Ishibashi et al., 1996; Schwarz et al., 1996). Whether Baf60a is
required for this compensatory response when the primary bile
acid biosynthesis pathway is defective remains unknown.
Gain- and loss-of-function studies indicate that Baf60a regulates
the expression of the bile acid metabolism gene program in a
cell-autonomous manner. At the physiological level, hepatic
Baf60a deficiency impaired bile acid production and intestinal
cholesterol absorption, resulting in elevated fecal excretion of
cholesterol.
Previous studies demonstrated that Baf60a forms a transcrip-
tional complex with PPARa and PGC-1a to regulate fatty acid
b-oxidation in hepatocytes (Li et al., 2008). Consistently, mRNA
expression of several genes involved in hepatic fat oxidation
was reduced in BaLKO mouse livers (data not shown). A some-
what unexpected finding in the current work is that hepatocyte-
specific deficiency of Baf60a markedly reduced the expression
of CAR. Our gain- and loss-of-function studies demonstrated
that Baf60a cell-autonomously induces the expression of CAR
through a feedforward regulatory loop. Accordingly, Baf60a defi-
ciency impaired the recruitment of the SWI/SNF complexes,
leading to reduced levels of chromatin marks characteristic of1666 Cell Reports 13, 1658–1669, November 24, 2015 ª2015 The Autranscriptional activation in hepatocytes. The SWI/SNF ATPase
subunit Brm has been shown to interact with Shp and modulate
feedback regulation of Cyp7a1 (Kemper et al., 2004). Surpris-
ingly, Baf60a deficiency does not appear to alter Cyp7a1 gene
expression. Previous studies demonstrated that TCPOBOP
treatments lowered plasma cholesterol levels in mice, in part
through increased cholesterol catabolism and inhibition of lipo-
genesis (Masson et al., 2008; Sberna et al., 2011a, 2011b). It is
possible that the discrepancy between these studies and ours
is due to whole-body CAR activation versus liver-specific reduc-
tion of CAR signaling. Alternatively, it is possible that Baf60amay
target other additional transcription factors in the liver to modu-
late cholesterol metabolism. A future use of the CAR-null mice
will help determine the significance of CAR in the regulation of
bile acid and cholesterol metabolism by hepatic Baf60a in vivo.
Nevertheless, our results strongly suggest that hepatic Baf60a/
CAR pathway plays a unique role in bile acid and cholesterol ho-
meostasis. Therapeutic intervention of this pathway in the liver
may alter the course of diet-induced hyperlipidemia and reduce
the risk of atherosclerosis.
EXPERIMENTAL PROCEDURES
Animal Studies
For the generation of Baf60a liver-specific knockout (BaLKO) mice, a targeting
vector that carries two loxP sites flanking exons 3 to 5 of mouse Baf60a gene
was constructed using BAC recombineering (Figure S1A). C57BL/6J ES cell
line (Bruce 4) from Transgenic Animal Model Core at the University of Michigan
was chosen for homologous recombination to facilitate breeding into C57BL/
6J genetic background for metabolic studies. Transgenic mice expressing the
CRE recombinase driven by liver-specific albumin prompter (Alb-CRE) were
used to cross with Baf60a flox/flox mice to achieve hepatic-specific deletion
of Baf60a. Mice were maintained in 12/12-hr-light/dark cycles and fed with
normal rodent chow or Western diet (D12079B, Research Diets) as indicated.
All animal studies were performed according to procedures approved by the
University Committee on Use and Care of Animals. For in vivo adenovirus
transduction, recombinant adenoviruses expressing GFP alone, FH-Baf60a,
or FH-CAR were generated using AdEasy adenoviral vector system (Strata-
gene) and transduced into mice through tail-vein injection. Prior to the final
experiments, all adenoviruses were titrated in mice and monitored for the
expression of GFP and adenoviral gene AdE4 to ensure similar doses were
administered. For ezetimide treatment, ezetimide was suspended in vehicle
(0.5% Hydroxyethylcellulose + 0.2% Tween 80) and administrated to mice
through oral gavage for 4 days. Vehicle alone was used for the control
treatment.
Primary Hepatocyte Isolation and Adenovirus Transduction
Primary hepatocytes were isolated using collagenase (type II, Worthington
CLS2), as previously described (Li et al., 2008). Cells were maintained in
DMEM containing 10% bovine growth serum and transduced with recombi-
nant adenoviruses at similar moiety of infection (MOI) for 24 hr, followed by
RNA isolation and gene expression analysis, or ChIP assays.
Coimmunoprecipitation and ChIP
HEK293T cells were transiently transfected with HA-CAR and Myc-Baf60a
for 24 hr. Total lysates or immunoprecipitated proteins were analyzed by west-
ern blot using antibodies against c-Myc (Sigma, C3956; 1:2,000) or HA (Santa
Cruz Biotechnology, sc-66181; 1:2,000). ChIP assay was performed accord-
ing to the protocol developed by Upstate Biotechnology as described (Meng
et al., 2014). In brief, liver nuclei or primary hepatocytes were fixed with 1%
formaldehyde and sonicated to produce chromatin lysates. The lysates
were pre-cleared with protein G agarose beads and immunoprecipitated over-
night with antibodies against Ace-H3 (Millipore, 06-599), H3K4m3 (Millipore,thors
07-473), Brg1 (Santa Cruz, sc-17796x), or control immunoglobulin G (IgG) in
the presence of BSA and salmon sperm DNA. The next day, protein G agarose
beads were added to each immunoprecipitation reaction for 1 hr, followed by
extensively wash and reverse crosslink. DNA was eluted from the beads and
purified using a PCR Purification Kit (Invitrogen) and subsequently analyzed
by qPCR using primers located on the proximal CAR promoter. Primers are
available upon request.
Gene Expression and Western Blot Analyses
TRIzol reagent (Life Technologies) was used to extract total RNA from tissues
and cultured primary hepatocytes. Gene expression analyses were performed
using SYBR Green reagent (Life Technologies). Relative abundance of mRNA
was normalized to ribosomal protein 36B4. For total protein extracts, frozen
liver samples were homogenized in a lysis buffer containing 50 mM Tris (pH
7.5), 150 mM NaCl, 5 mM NaF, 25 mM b-glycerol phosphate, 1 mM sodium
orthovanadate, 10%glycerol, 1%Triton X-100, 1mMDTT, and protease inhib-
itor cocktail (Roche). For liver nuclear protein extracts, frozen livers were ho-
mogenized using a Dounce homogenizer in ice-cold homogenization buffer
containing 0.6% NP40, 150 mM NaCl, 10 mM HEPES (pH 7.9), 1 mM EDTA,
and protease inhibitor cocktail (Roche). The homogenates were centrifuged
at 700 rpm for 1 min at 4C to remove tissue debris. The suspension was
transferred to a new 15-ml tube and centrifuged at 3,000 rpm for 5 min at
4C. The nuclei pellet was washed with homogenization buffer and resus-
pended in a low-salt buffer containing 20 mM Tris (pH 7.5), 25% glycerol,
1.5 mMMgCl2, 200 mM EDTA, 20 mM KCl, and protease inhibitor cocktail, fol-
lowed by the addition of a high-salt buffer (1/2 volume) containing 20 mM Tris
(pH 7.5), 1.5mMMgCl2, 200 mMEDTA, 1.2MKCl, and protease inhibitor cock-
tail. The homogenates were rotated for 2 hr at 4C and centrifuged at
13,000 rpm for 20 min at 4C to remove the cell debris. For immunoblotting
assays, total protein lysates or liver nuclear extracts were separated by
SDS-PAGE gels and transferred to a polyvinylidene difluoridemembrane (Milli-
pore), followed by immunoblotting with the following primary antibodies. Rab-
bit polyclonal antibody to Baf60c was generated with the recombinant GST
fusion mouse Baf60c protein and affinity purified. Antibody against Baf60a
(1:1,000, 611728) was from BD Transduction Laboratories. Antibody against
Baf53a (1:1,000, 10341-1-AP) was from Proteintech. Antibody against Lamin
A/C (1:2,000, 2032) was from Cell Signaling Technology. Antibodies against
c-Myc (1:2,000, C3956) and b-actin (1:2000, A4700) were from Sigma. Anti-
bodies against HA (1:2,000, sc-66181), Brg1 (1:1,000, sc-17796x), Baf155
(1:2,000, sc-10756x), and Baf170 (1:1,000, sc-10757x) were from Santa
Cruz. Antibody against LDLR (1:1,000, ab52818) was from Abcam.
Plasma Analysis
For the lipoprotein profiling, pooled plasma samples from three flox/flox or
three BaLKO mice were fractionated by fast protein liquid chromatography.
The concentrations of cholesterol in each fraction were measured. HDL and
VLDL/LDL cholesterol in individual plasma samples were separated and
measured using HDL and LDL/VLDL Quantification Colorimetric Kit (Bio-
Vision). Plasma concentrations of triglycerides and NEFA were measured us-
ing commercial assay kits from Sigma and Wako Diagnostics, respectively.
Plasma concentrations of total cholesterol, ALT, and AST were measured
using assay kits from Stanbio Laboratory. Plasma Pcsk9 level was measured
using the mPcsk9 ELISA kit (Circulex).
3H-Cholesterol Absorption Assay
Acute cholesterol absorption assay was performed as described (Li et al.,
2014). Mice were oral gavage with [1,2-3H(N)]-cholesterol (5 mCi and 0.1 mg
unlabeled cholesterol in 0.2 ml corn oil). Two hours later, the mice were eutha-
nized, and plasma and liver samples were harvested. Livers were weighed
(100 mg/mouse) and homogenized in 1 ml chloroform/methanol (2:1, v/v), fol-
lowed by rotation at 37C for 4 hr, and spun at 2,0003 g for 10 min. Radioac-
tivity in triplicate aliquots of plasma and liver extracts was measured by liquid
scintillation counting.
Bile Acid Analysis
Control and BaLKOmice fed withWD for 12 weeks were anesthetized. Plasma
samples were collected via heart puncture. The gallbladder was removed afterCell Repcommon bile duct ligation and transferred to a pre-weighed Eppendorf tube.
The bile content in the gallbladder was weighed and converted into volume
assuming a density of 1 mg/ml. Liver was dissected, weighed, and homoge-
nized in 75% ethanol. The homogenate was incubated at 50C for 2 hr to
extract bile acids and centrifuged at 6,000 3 g for 10 min. Bile acid content
in the supernatant was measured. Total bile acid concentrations in plasma,
bile, and liver extracts were determined using a Total Bile Acid Assay Kit
(BQ 092A-EALD, BQKits).
The concentration of different bile acids in the gallbladder was measured
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as
described previously (Perwaiz et al., 2001). In brief, bile samples were diluted
1:200 and 1:10,000 in methanol/water (1:1, v/v). Standard curve was gener-
ated with ACS grade analytical standard bile acid compounds inmethanol/wa-
ter (1:1, v/v) via serial dilution using propyl hydroxyl benzoate as internal stan-
dard. 10 ml of each sample was loaded to a Thermo Scientific Betabasic-18
100 3 2.1 mm, pore size 5-mm column, eluted with 0.1% formic acid in water
as mobile phase A and methanol as mobile phase B in 20 min at 0.2 ml/min,
and analyzed with a ABSciex 3200 QTRAP mass spectrometer using negative
ESI MRM mode.
The bile acid pool size was measured as previously described (Li et al.,
2011). In brief, after the mice were weighed, anesthetized, and exsanguinated,
the fresh organs and their contents were collected, minced, and extracted in
20 ml of 95% ethanol at 50C overnight, followed by spin at 6,000 3 g at
4C for 10 min and collection of the supernatant as extract. The extraction
was repeated with another 20 ml of 85% ethanol and 20 ml of 75% ethanol
at 50C for 2 hr, sequentially. All the three extracts were combined and sub-
jected for bile acid measurement using the Bile Acid Assay Kit (BQ 092A-
EALD, BQ Kits).
Evaluation of Atherosclerosis
Atherosclerosis studies were conducted as described (Chang et al., 2012). In
brief, mice were anesthetized and subjected to whole-body perfusion to fix the
tissues. The entire aorta was micro-dissected from each mouse. Atheroscle-
rosis was identified by en face oil red O staining, followed by imaging and
lesion area quantification using ImageJ software.
Statistics
Data were analyzed using the unpaired two-tailed Student’s t test for indepen-
dent groups. A p value <0.05 was considered statistically significant.ACCESSION NUMBERS
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